Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
Recent studies have described a reduced incidence or the regression of Kaposi's sarcoma (KS)
in HIV-infected patients treated with the highly active anti-retroviral therapy (HAART) that
contains at least one inhibitor of the HIV protease (HIV-PI) such as Indinavir. Experimental
studies have shown that part of the anti-KS actions of HIV-PI are not related to their
antiretroviral actions, but, at least in part, to their capability of blocking angiogenesis
and tumor growth.
This study will be conducted on HIV-negative (classical) KS patients to prove that Indinavir
has anti-angiogenic and anti-KS effects in humans independently of its antiretroviral
activity.
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Superiore di SanitÃ
Treatments:
HIV Protease Inhibitors Indinavir Protease Inhibitors